TOTeppei Okamoto

Teppei Okamoto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Teppei Okamoto has a total of 257 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Discordance between G8 and functional competence and their associations with quality of life in urological cancers

    by Fumiya Yoneyama, Takuma Narita, Tomoko Hamaya, Osamu Soma, Kyo Togashi, Marino Sawai, Anna Yoneyama, Jotaro Mikami, Naoki Fujita, Teppei Okamoto, et al.

  • Association of time to upfront treatment initiation with outcomes in metastatic hormone-sensitive prostate cancer: a 4-month landmark analysis

    by Eisuke Iwaori, Takafumi Yanagisawa, Shintaro Narita, Wataru Fukuokaya, Fumihiko Urabe, Naoki Fujita, Hiromi Sato, Tomoko Hamaya, Takuma Narita, Teppei Okamoto, et al.

  • Treatment Patterns and Outcomes After Recurrence Following Adjuvant Nivolumab for Urothelial Carcinoma: An AGEHA Real‐World Study

    by Izuki Ogawa, Takuma Narita, Masanao Shinohara, Yohei Kawashima, Yuya Sekine, Shintaro Narita, Shin Kobayashi, Noriyuki Abe, Shunsuke Tazawa, Naoki Fujita, et al.

    Objectives: To describe post‐recurrence treatment patterns and outcomes after adjuvant nivolumab for urothelial carcinoma in real‐world practice. Methods: We retrospectively analyzed patients with urothelial carcinoma who underwent radical cystectomy or nephroureterectomy followed by adjuvant nivolumab in the multicenter AGEHA database. Among 141 patients, 40 developed recurrence, excluding non‐muscle‐invasive bladder recurrence. First‐line post‐recurrence treatment was categorized as enfortumab vedotin plus pembrolizumab (EVP), enfortumab vedotin (EV), non‐EV regimens, or no systemic therapy. Overall survival (OS) was measured from recurrence and progression‐free survival (PFS) from initiation of first‐line post‐recurrence therapy. Results: Of 141 patients treated with adjuvant nivolumab, 40 (28%) developed recurrence. First‐line post‐recurrence treatment was EVP in 10 patients, EV in 15, non‐EV regimens in 12, and no systemic therapy in 3. Median time from surgery and nivolumab initiation to recurrence was 5.9 and 4.2 months, respectively. Median OS from recurrence was 27.1, 26.0, and 23.4 months in the EVP, EV, and non‐EV groups, respectively, while median PFS from initiation of first‐line post‐recurrence therapy was 12.9, 7.6, and 8.7 months. Baseline characteristics differed across groups, particularly in recurrence timing and metastatic sites, and EV‐based therapy was frequently selected after recurrence. Conclusions: Recurrence after adjuvant nivolumab occurred in 28% of patients in real‐world practice. Post‐recurrence management was heterogeneous, and EV‐based therapy was frequently used in this setting. These findings provide hypothesis‐generating real‐world evidence on treatment sequencing after adjuvant nivolumab and require validation in larger cohorts with longer follow‐up.

  • Open Access

    Real-world patterns of first-line treatment selection after the introduction of enfortumab vedotin plus pembrolizumab for advanced urothelial carcinoma

    by Keita Ishimoto, Takuma Narita, Yuya Sekine, Masanao Shinohara, Naoki Fujita, Yohei Kawashima, Shintaro Narita, Shin Kobayashi, Noriyuki Abe, Jotaro Mikami, et al.

  • Visualizing Baseline Eligibility Across Locally Advanced or Metastatic Urothelial Cancer Trials and Real‐World Cohorts

    by Takaki Ichiyama, Takuma Narita, Hiroyuki Sato, Yuya Sekine, Masanao Shinohara, Yohei Kawashima, Mizuki Kobayashi, Kazuyuki Numakura, Jotaro Mikami, Naoki Fujita, et al.

    Background: Clinical trials in locally advanced or metastatic urothelial carcinoma (mUC) often enroll younger and fitter patients than those treated in routine practice, limiting applicability to real‐world populations. We developed a simple descriptive metric, the eligibility gap (EG) score, to place trial and real‐world cohorts on a common scale and summarize differences in baseline eligibility profiles. Methods: Pivotal clinical trials were identified through a PubMed search, and three real‐world datasets from Japan, the United States, and Spain were included. The EG score used three consistently reported domains: age, ECOG performance status, and cisplatin eligibility. Each domain was scaled from 0 to 33.3 points and summed to yield a score from 0 to 99.9, with higher scores indicating younger, fitter populations. Robustness was assessed across alternative model specifications, including prespecified weighting schemes, random‐weight simulations, alternative age and ECOG scoring functions, and one‐domain‐out analyses. Results: EG scores were generally higher in cisplatin‐based trials (74.8–90.1) than in immune checkpoint inhibitors (ICI)‐based trials (52.3–81.2) and real‐world cohorts (35.1–45.5), while the cisplatin‐ineligible trial had the lowest score (24.5). Alternative age transformations and a linear ECOG model did not change ranking. In one‐domain‐out analyses, omission of ECOG preserved ranking, whereas omission of age or cisplatin‐fitness produced minor shifts. Across prespecified weighting schemes, rank‐order concordance remained high (Spearman's rho = 0.982–1.000), and 10 000 random‐weight simulations showed a median rho of 0.982. Conclusions: The EG score may provide a simple descriptive summary of eligibility domains across mUC studies, with stable cohort ordering across alternative model specifications.

  • Open Access

    CT-based renal artery caliber change as a potential imaging marker of treatment response in renal cell carcinoma; an exploratory imaging study

    by Himawari Asanuma, Teppei Okamoto, Tadashi Yoshizawa, Takuya Oishi, Tomoko Hamaya, Hirotake Kodama, Takuma Narita, Jotaro Mikami, Naoki Fujita, Tohru Yoneyama, et al.

    To evaluate whether treatment-induced changes in tumor-bearing renal artery caliber on contrast-enhanced CT are associated with pathological response and p

  • Association of Prophylactic Intravenous Corticosteroid Premedication With Toxicity and Survival in Patients Receiving Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma

    by Masanao Shinohara, Hayato Yamamoto, Yohei Kawashima, Yuya Sekine, Shintaro Narita, Shin Kobayashi, Noriyuki Abe, Hirotake Kodama, Naoki Fujita, Teppei Okamoto, et al.

    Objectives: Enfortumab vedotin (EV) is the standard treatment for locally advanced or metastatic urothelial carcinoma (la/mUC), though skin toxicities are problematic. We evaluated whether prophylactic corticosteroid premedication is associated with reduced toxicity and survival outcomes. Methods: We retrospectively analyzed 157 patients with la/mUC receiving EV monotherapy, stratified by prophylactic intravenous dexamethasone (6.6 mg) premedication (pre‐EV steroid, n = 20) or not (no pre‐EV steroid, n = 137). Endpoints included the incidence of EV‐related adverse events (AEs), objective response rate (ORR), progression‐free survival (PFS), and overall survival (OS). Inverse probability of treatment weighting (IPTW) was used to adjust for baseline imbalances. Results: Corticosteroid premedication was associated with a significantly lower incidence of skin AEs (10% vs. 62.7%, p < 0.001) and a reduced number of cumulative AEs (median 1 vs. 2, p = 0.018). The ORR were comparable. However, patients with steroid premedication showed inferior OS compared to those without (median OS 10.3 vs. 17.4 months, p = 0.008), while PFS showed no significant difference. Multivariable analysis confirmed corticosteroid premedication as an independent predictor of reduced skin AEs (OR 0.08, p = 0.001); however, it was associated with worse OS (HR 1.91, p = 0.048), with no significant impact on PFS. In the IPTW‐adjusted analysis, corticosteroid premedication remained significantly associated with worse OS. Conclusions: Corticosteroid premedication reduces skin toxicities during EV monotherapy, but its impact on survival remains uncertain and requires validation in larger studies.


  • Open Access

    Overactive Bladder Symptoms as a Predictor of Longitudinal Decline in Grip Strength in Community‐Dwelling Men: A 4‐Year Longitudinal Study

    by Hiroyuki Sato, Teppei Okamoto, Tomoko Hamaya, Hirotake Kodama, Takuma Narita, Jotaro Mikami, Naoki Fujita, Hayato Yamamoto, Atsushi Imai, Koichi Murashita, et al.

    Objectives: Lower urinary tract symptoms (LUTS) are associated with sarcopenia in men. However, it is not clear whether LUTS are related to the decline in physical function. We investigated the longitudinal association between the LUTS severity and the grip strength change in community‐dwelling men. Methods: A 4‐year longitudinal study was conducted using data from 151 men (median age 53 years) enrolled in the Iwaki Health Promotion Project. Grip strength change was calculated as the difference between 2015 and 2019 measurements. LUTS severity was assessed with the International Prostate Symptom Score (IPSS) and the Overactive Bladder Symptom Score (OABSS). Baseline variables included age, Aging Male Symptoms score, serum testosterone, albumin, interleukin‐6, HbA1c, daily exercise, skeletal muscle mass index, and percent body fat. Correlations and multiple regression analyses were performed. Results: The median age and baseline grip strength were 53 years and 41.3 kg, respectively. Grip strength decreased significantly after 4 years, with a median value of −1.1 kg. There was a significant negative correlation between total OABSS, OABSS Q3 (frequency of urinary urgency, r = −0.234, p = 0.003), Q4 (frequency of urge urinary incontinence, r = −0.190, p = 0.020), and grip strength change, whereas the IPSS voiding symptoms domain was not. Multiple regression analysis showed that only the total score of OABSS Q3 and Q4 was significantly correlated with grip strength change (standardized β = −0.930, p = 0.012). Conclusions: The main symptoms of OAB may be indicators of the grip strength decline in men.

  • Open Access

    Serum Serotonin Levels as a Potential Risk Factor for Overactive Bladder in a Community‐Dwelling Population: A Four‐Year Longitudinal Study

    by Takafumi Fukushima, Teppei Okamoto, Tomoko Hamaya, Hirotake Kodama, Naoki Fujita, Hayato Yamamoto, Atsushi Imai, Shigeyuki Nakaji, Shingo Hatakeyama

    Purpose: This study aims to investigate the potential influence of serum serotonin (5‐HT) levels on the development of overactive bladder (OAB) in a community‐dwelling population.Methods: A four‐year longitudinal study was conducted involving 615 subjects who participated in the Iwaki Health Promotion Project in Hirosaki, Japan, in both 2015 and 2019. OAB was defined as experiencing urinary urgency at least once a week with an Overactive Bladder Symptom Score (OABSS) of ≥ 3. Baseline data from 2015, including serum 5‐HT levels, other laboratory data, and comorbidity information, were used for the analysis. The association between serum 5‐HT levels and incident OAB in 2019 (OAB‐2019) was examined using multivariate logistic regression analyses.Results: The study included 250 men and 365 women, of whom 74 individuals (29 men and 45 women) met the diagnostic criteria for OAB in 2019. Significant differences were observed between the OAB‐2019 and non‐OAB‐2019 groups, including age, chronic kidney disease, irritable bowel syndrome, hypertension, glycemic status, mental status, and OAB in 2015. Participants in the OAB‐2019 group had significantly lower serum 5‐HT levels compared to the non‐OAB‐2019 group (100 vs. 129 ng/mL, p < 0.001). After adjusting for confounders, multivariable analysis revealed that serum 5‐HT levels < 134 ng/mL (odds ratio: 2.48, 95% confidence interval: 1.39–5.83, p = 0.004), age, mental status, and OAB in 2015 independently served as risk factors for OAB‐2019.Conclusions: Low serum 5‐HT levels may be associated with an increased risk of OAB. Further research is needed to elucidate the underlying mechanisms responsible for this association.


  • Open Access

    The long-term impact of mild COVID-19 on cardiovascular disease and mortality in patients on hemodialysis: a post-Omicron era retrospective observational study

    by Akiko Okamoto, Teppei Okamoto, Takaki Ichiyama, Takafumi Fukushima, Sosuke Omizo, Himawari Asanuma, Hiroyuki Sato, Hisashi Sakurai, Anna Yoneyama, Fumiya Yoneyama, et al.

    The long-term cardiovascular (CVD) and mortality risk associated with mild COVID-19 infections in patients on hemodialysis (HD) during the post-Omicron era remains unclear. This study evaluates clinical outcomes in patients on HD following Omicron infection. This retrospective observational study included 462 patients from a single center. All mild COVID-19 cases occurred after January 2022. The first analysis compared patients with prior mild COVID-19 (COVID-19 history [+], n = 63) to those never infected including the observational period (COVID-19 infection [-], n = 286). The second analysis included 392 patients without prior infection, comparing those who acquired mild COVID-19 during follow-up (COVID-19 infection [+]) with those in the COVID-19 infection [-] group. The primary outcome was CVD events. Multivariate analyses assessed COVID-19 infections's impact on clinical outcomes. After 761 days, 100 CVD events including 51 cardiovascular deaths and 58 non-CVD deaths occurred. The CVD risk did not significantly differ between the COVID-19 history (+) and infection (-) groups (Hazard ration [HR]: 0.50, 95% confidence interval [CI]: 0.25-1.01, p = .054) as well as non-CVD mortality. In the second analysis, patients with newly acquired COVID-19 did not exhibit a significantly increased risk of CVD (HR: 0.55, 95% CI: 0.25-1.19, p = .132) or non-CVD mortality. Mild COVID-19 infections does not significantly increase long-term CVD and mortality risk in patients on HD in the post-Omicron era.